Rokea A El-Azhary

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3234370/publications.pdf

Version: 2024-02-01

54 papers 1,160 citations

361045 20 h-index 395343 33 g-index

54 all docs 54 docs citations

54 times ranked 1125 citing authors

#	Article	IF	Citations
1	Differences between Stevensâ€Johnson syndrome versus toxic epidermal necrolysis. International Journal of Dermatology, 2021, 60, 53-59.	0.5	6
2	Disseminated intravascular coagulopathy: a complication of Stevens–Johnson syndrome/toxic epidermal necrolysis. International Journal of Dermatology, 2021, 60, 185-189.	0.5	3
3	Retrospective analysis of 578 inpatient dermatology consultations in hematology and hematopoietic stem cell transplant patients. International Journal of Dermatology, 2021, 60, 1385-1391.	0.5	1
4	Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review. Transplantation and Cellular Therapy, 2021, 27, 738-746.	0.6	4
5	Focus Africa. International Journal of Dermatology, 2020, 59, 519-519.	0.5	0
6	Melanoma in a patient with previously unrecognized Birt-Hogg-Dubà $\ \ $ syndrome. JAAD Case Reports, 2019, 5, 947-952.	0.4	1
7	Adalimumabâ€induced erythrodermic reactions. International Journal of Dermatology, 2019, 58, e204-e206.	0.5	4
8	Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013. Journal of the American Academy of Dermatology, 2019, 80, 1658-1663.	0.6	35
9	Chemotherapyâ€induced skin toxicity and capillary leak syndrome. International Journal of Dermatology, 2019, 58, 856-860.	0.5	4
10	The inevitability of change. Clinics in Dermatology, 2019, 37, 4-11.	0.8	9
11	Evaluating the validity of subclassifying warfarinâ€associated nonuremic calciphylaxis: a retrospective cohort study. International Journal of Dermatology, 2018, 57, 572-574.	0.5	8
12	Dermatologic manifestations of solid organ transplantation–associated graft-versus-host disease: A systematic review. Journal of the American Academy of Dermatology, 2018, 78, 1097-1101.e1.	0.6	16
13	Treatment of severe drug reactions by hemodialysis. International Journal of Dermatology, 2018, 57, 177-182.	0.5	8
14	Strengthening the Case for the Role of Thrombophilia in Calciphylaxis. JAMA Dermatology, 2018, 154, 970.	2.0	1
15	Clinical and histopathologic manifestations of solid organ transplantationâ€associated graftâ€versusâ€host disease involving the skin: A singleâ€center retrospective study. Journal of Cutaneous Pathology, 2018, 45, 817-823.	0.7	7
16	Prevalence of allergen sensitization detected by patch tests. Allergy and Asthma Proceedings, 2018, 39, 240-244.	1.0	2
17	Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996–2013. International Journal of Dermatology, 2017, 56, 405-414.	0.5	44

#	Article	IF	CITATIONS
19	Immunophenotypic and molecular comparison between allogeneic and autologous graftâ€vsâ€host disease of the skin: A retrospective study using immunohistochemical and proteomics methods. Journal of Cutaneous Pathology, 2017, 44, 1087-1091.	0.7	2
20	Direct oral anticoagulant medications in calciphylaxis. International Journal of Dermatology, 2017, 56, 1065-1070.	0.5	29
21	Cutaneous manifestations of graftâ€versusâ€host disease: role of the dermatologist. International Journal of Dermatology, 2017, 56, 131-140.	0.5	28
22	The last bastion of collegiality: the peerâ€review process in the era of open access. International Journal of Dermatology, 2016, 55, 247-248.	0.5	2
23	Exfoliative erythroderma after tumor necrosis factor-αinhibitor therapy. International Journal of Dermatology, 2016, 55, e214-e215.	0.5	4
24	Survival, Risk Factors, and Effect of Treatment in 101 Patients With Calciphylaxis. Mayo Clinic Proceedings, 2016, 91, 1384-1394.	1.4	145
25	Calciphylaxis: A Disease of Pannicular Thrombosis. Mayo Clinic Proceedings, 2016, 91, 1395-1402.	1.4	42
26	Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013. Journal of the American Academy of Dermatology, 2016, 75, 931-939.	0.6	38
27	Filling a critical practice gap: experience with a dermatology day treatment center at Mayo Clinic. International Journal of Dermatology, 2015, 54, 600-604.	0.5	3
28	Experience of a year of adult hospital dermatology consultations. International Journal of Dermatology, 2015, 54, 1150-1156.	0.5	29
29	Kaposi varicelliform eruption in patients with Darier disease: A 20-year retrospective study. Journal of the American Academy of Dermatology, 2015, 72, 481-484.	0.6	21
30	Cutaneous manifestations of immunoglobulin <scp>G</scp> 4â€related disease: what dermatologists need to know. International Journal of Dermatology, 2015, 54, 377-382.	0.5	1
31	Acute cutaneous graftâ€vs.â€host disease compared to drug hypersensitivity reaction with vacuolar interface changes: a blinded study of microscopic and immunohistochemical features. Journal of Cutaneous Pathology, 2015, 42, 39-45.	0.7	23
32	Postoperative pyoderma gangrenosum (PG): The Mayo Clinic experience of 20 years from 1994 through 2014. Journal of the American Academy of Dermatology, 2015, 73, 615-622.	0.6	88
33	Cutaneous microemboli from hydrophilic polymer after endovascular procedures. Journal of the American Academy of Dermatology, 2015, 73, 666-671.	0.6	33
34	Anticipating and preventing infection in patients treated with immunosuppressive medications for dermatologic indications: A dermatologist's checklist. Journal of the American Academy of Dermatology, 2014, 71, e125-e126.	0.6	1
35	Missed opportunities in residency education: The role of hospital dermatology. Journal of the American Academy of Dermatology, 2013, 68, 677-678.	0.6	5
36	Pharmacogenetics in dermatology: a patientâ€eentered update. International Journal of Dermatology, 2013, 52, 1005-1012.	0.5	2

#	Article	IF	Citations
37	Pediatric Hospital Dermatology: Experience with Inpatient and Consult Services at the Mayo Clinic. Pediatric Dermatology, 2013, 30, 433-437.	0.5	24
38	Retrospective Analysis of Tissue Plasminogen Activator as an Adjuvant Treatment for Calciphylaxis. JAMA Dermatology, 2013, 149, 63.	2.0	35
39	Chemokine Responses in Palladium-Induced Lichenoid Eruption. Dermatitis, 2012, 23, 180-181.	0.8	0
40	Thioguanine Nucleotides and Thiopurine Methyltransferase in Immunobullous Diseases. Archives of Dermatology, 2009, 145, 644-52.	1.7	12
41	A 10-Year Retrospective Study on Palladium Sensitivity. Dermatitis, 2009, 20, 208-213.	0.8	37
42	Sclerotherapy of spider veins using the accurate depth-gauge collagen needle. International Journal of Dermatology, 2008, 47, 205-206.	0.5	5
43	Sweet Syndrome as a Manifestation of Azathioprine Hypersensitivity. Mayo Clinic Proceedings, 2008, 83, 1026-1030.	1.4	37
44	Antihistone antibodies in linear scleroderma variants. International Journal of Dermatology, 2006, 45, 1296-1299.	0.5	22
45	Oral bexarotene in a therapy-resistant Sezary syndrome patient: observations on Sezary cell compartmentalization. International Journal of Dermatology, 2005, 44, 25-28.	0.5	10
46	Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: Development of extracutaneous lymphoma in 6 patientsâ^—. Journal of the American Academy of Dermatology, 2005, 52, 991-996.	0.6	33
47	Do Antihistone Autoantibodies Reflect Disease Activity in Linear Scleroderma?. Archives of Dermatology, 2004, 140, 759-60.	1.7	12
48	A new patient education approach in contact allergic dermatitis: the Contact Allergen Replacement Database (CARD)*. International Journal of Dermatology, 2004, 43, 278-280.	0.5	14
49	Azathioprine: current status and future considerations. International Journal of Dermatology, 2003, 42, 335-341.	0.5	33
50	Amyopathic dermatomyositis: Retrospective review of 37 cases. Journal of the American Academy of Dermatology, 2002, 46, 560-565.	0.6	139
51	Allergic contact dermatitis to epoxy resin in immersion oil for light microscopy. Journal of the American Academy of Dermatology, 2002, 47, 954-955.	0.6	8
52	Treatment of late-stage Sezary syndrome with 2-Chlorodeoxyadenosine. International Journal of Dermatology, 2002, 41, 352-356.	0.5	16
53	EFFICACY OF CONTACT ALLERGEN REPLACEMENT DATABASE (CARD) IN THE TREATMENT OF ALLERGIC CONTACT DERMATITIS SECONDARY TO TOPICAL SKIN CARE PRODUCT USE. American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, 2001, 12, 124.	0.4	4
54	Contact allergen avoidance program: A topical skin care product database. American Journal of Contact Dermatitis: Official Journal of the American Contact Dermatitis Society, 2000, 11, 243-247.	0.4	11